A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.

A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.

PURPOSE: Tumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefi...

Full description

Bibliographic Details
Main Authors: Eustace, A, Mani, N, Span, P, Irlam, J, Taylor, J, Betts, G, Denley, H, Miller, C, Homer, J, Rojas, A, Hoskin, P, Buffa, F, Harris, A, Kaanders, J, West, C
Format: Journal article
Language:English
Published: 2013

Similar Items

Similar Items